Mycophenolate mofetil-induced pseudotumor cerebri in a boy with autoimmune lymphoproliferative disease

Patıroğlu, Türkan; Özcan, Alper; Karakükçü, Musa; Özdemır, Mehmet Akif; Poyrazoglu, Gamze; Canpolat, Mehmet; Ünal, Ekrem

doi:10.1007/s00381-011-1402-4

Cited by 8 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some less common adverse effects have been reported in children, as follows: an abnormal chromatin clumping syndrome in two children associated with leucocytosis [65]; pseudotumour cerebri syndrome in a 5‐year‐old child taking MMF for autoimmune lymphoproliferative disease [66]; and two cases of children with severe colitis [67]. Perhaps the most significant, albeit rare, adverse effects have been due to respiratory problems, including a single case of reversible chronic mineralizing pulmonary elastosis in a 7‐year‐old boy [68] and several instances of bronchiectasis [69, 70].…”

Section: Unresolved Issues With the Use Of Mmf In Childrenmentioning

confidence: 99%

Paediatric use of mycophenolate mofetil

Downing

Pirmohamed

Beresford

et al. 2012

Brit J Clinical Pharma

View full text Add to dashboard Cite

A number of medications do not have a licence, or label, for use in the paediatric age group nor for the specific indication for which they are being used in children. Over recent years, mycophenolate mofetil has increasingly been used off‐label (i.e. off‐licence) in adults for a number of indications, including autoimmune conditions; progressively, this wider use has been extended to children. This review summarizes current use of mycophenolate mofetil (MMF) in children, looking at how MMF works, the pharmacokinetics, the clinical conditions for which it is used, the advantages it has when compared with other immunosuppressants and the unresolved issues remaining with use in children. The review aims to focus on off‐label use in children so as to identify areas that require further research and investigation. The overall commercial value of MMF is limited because it has now come off patent in adults. Given the increasing knowledge of the pharmacodynamics, pharmacokinetics and pharmacogenomics demonstrating the clinical benefits of MMF, new, formal, investigator‐led studies, including trials focusing on the use of MMF in children, would be of immense value.

show abstract

Section: Unresolved Issues With the Use Of Mmf In Childrenmentioning

confidence: 99%

Paediatric use of mycophenolate mofetil

Downing

Pirmohamed

Beresford

et al. 2012

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In children, the warm AIHA is generally provoked by viral infections and hemolysis may occur. In the literature, warm AIHA cases caused by basic viral infections such as mycoplasma, parvovirus, HBV and HCV, cytomegalovirus, varicella, toxoplasma and Ebstein-Barr virus were reported (3,9,(15)(16)(17)(18). While non-specific infections were detected in most of our patients, 1 had varicella, 1 had HBV, 1 had HEV and 1 had tuberculosis infection.…”

Section: Discussionmentioning

confidence: 56%

The spectrum of underlying diseases in children with autoimmune hemolytic anemia

Özcan

Cansever

Yılmaz

et al. 2021

Journal of Health Sciences and Medicine

View full text Add to dashboard Cite

Aim: Autoimmune hemolytic anemia (AIHA) is characterized by the production of antibodies directed against red blood cells. We aimed to describe the clinical presentation, hematologic and biochemical profiles, treatment modalities, underlying diseases and outcomes in children suffering from AIHA. Material and Method: In a retrospectively manner, we consecutively recrutied 62 children (aged 1 month-18 years) with AIHA who had been followed in Erciyes University Child Hospital between January, 2000 and November, 2017. Results: The mean age at time of diagnosis was 61.9±51.9 months (range:1-192) in 62 children including 28 girls and 34 boys. The most common complaints included fatigue and fever while the most common findings were jaundice and hepatosplenomegaly. In 22 children (35.4%), there was a comorbid, active, non-specific infection (upper respiratory tract infection, lower respiratory tract infection, diarrhea, urinary tract infection). At time of diagnosis, mean hemoglobin (Hb) level was 6.9±2.5 g/dL (range: 5-9). The glucocorticoid therapy was given in majority of the patients while no medical treatment was given to 4 patients. Of the patients with primary AIHA, 6 patients were unresponsive to the treatment while one patient responded partially. It was found that there were underlying risk factors in 36 patients with secondary AIHA, as immunodeficiency and autoimmune disorders being the most common risk factors. Conclusion: The immunodeficiencies were highly prevalent in children included. By advance of whole exome sequencing technology, we believe that primary immunodeficiencies was the most common underlying disease in our study detected quite high in presented children.

show abstract

“…Pseudotumor cerebri (PTC) is a condition characterized by elevated intracranial pressure without an intracranial mass, inflammation, vascular abnormality, hydrocephalus on radiological examination, or changes in level of consciousness. [1][2][3][4][5] PT affects 0.71 out of every 100,000 children. 6,7 It is a rare condition in infants, with an estimated prevalence of 0.17 to 1.32 per 100,000 children.…”

Section: Introductionmentioning

confidence: 99%

Etiology and prognosis of childhood pseudotumor cerebri syndrome: A retrospective single center study from Turkey

Güven¹,

Aydoğdu²,

Sarıcı³

2022

NeuroAsia

View full text Add to dashboard Cite

Objective: This study aim to investigate children who were diagnosed with pseudotumor cerebri (PTC) from a tertiary hospital in Turkey. Methods: This was a retrospective study based on medical records of 16 children diagnosed with PTC. All patients were followed up in the Pediatric Neurology Department of Keçiören Training and Research Hospital, between 2017 and 2021. Clinical and laboratory features of patients were reviewed. Results: Among the 16 patients diagnosed with pseudotumor cerebri, 50% were girls and 50% boys. The mean age at the disease onset was 12± 3.8 years (range: 4-17 years). Eleven patients (68.8%) were in the pubertal period and, five (31.3%) of them were in pre-pubertal period. Five patients (31.3%) were diagnosed with primary and eleven (68.8%) patients with secondary PTC. Underlying etiologies were obesity (37.5%), sinusitis (37.5%), and systemic lupus erythematosus (6.3%). Laboratory findings revealed vitamin D deficiency (68.8%); vitamin B12 deficiency (25%), iron deficiency anemia (12.5%), and vitamin A deficiency (6.3%). The most common symptoms were headache (93.8%), nausea and vomiting (25%), blurred vision (18.8%), photophobia (18.8%). All patients had bilateral papilledema. Four children were asymptomatic with papilledema detected incidentally on routine eye examination. Nine patients received medical treatment. Acetazolamide was the most prescribed medication (56%). Only one patient with epilepsy had combined treatment with topiramate, acetazolamide and then lumboperitoneal shunt. All patients responded to treatment with full recovery. Conclusion: PTC is not rare in children, most were pubertal, and a quarter were asymptomatic diagnosed in routine fundus examination.

show abstract

Mycophenolate mofetil-induced pseudotumor cerebri in a boy with autoimmune lymphoproliferative disease

Cited by 8 publications

References 7 publications

Paediatric use of mycophenolate mofetil

Paediatric use of mycophenolate mofetil

The spectrum of underlying diseases in children with autoimmune hemolytic anemia

Etiology and prognosis of childhood pseudotumor cerebri syndrome: A retrospective single center study from Turkey

Contact Info

Product

Resources

About